Results 211 to 220 of about 133,537 (299)

Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach [PDF]

, 2013
Bearzi Italo, Bianconi Maristella, Bittoni Alessandro, Cascinu Stefano, Cecchini Luca, Del Prete Michela, Faloppi Luca, Giampieri Riccardo, Mandolesi Alessandra, Pistelli Mirco, SCARTOZZI, MARIO   +10 more
core   +1 more source

Establishment and Characterization of MCA23, a Novel Mouse Intrahepatic Cholangiocarcinoma Cell Line

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Introduction Intrahepatic cholangiocarcinoma (ICC) is an aggressive type of malignancy. Recent advancements have highlighted the importance of the tumor immune microenvironment in therapeutic responses and prognosis. However, the lack of a mouse‐derived ICC cell line and current mouse models limit explorations of the TME in ICC.
Yuchao He, Yi Luo, Liwei Chen, Yu Wang, Bei Liu, Mengting Sun, Wenchen Gong, Xiangdong Tian, Lin Guo, Qin Zhang, Qiang Wu, Lu Chen, Hua Guo   +12 more
wiley   +1 more source

Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Purpose Identify factors influencing audiological care for chemotherapy‐induced ototoxicity from the perspectives of oncology providers in the Veterans Health Administration (VA), and quantify audiology service use among Veterans receiving ototoxic chemotherapies.
Cecilia Lacey, Khaya Clark, James Riley Debacker, Hunter Stuehm, Michelle Hungerford, Trisha Milnes, Kirsten Johansson, Rosemarie Mannino, Julie N. Graff, Dawn Konrad‐Martin   +9 more
wiley   +1 more source

Liposomal Delivery of Pyronaridine as a Repurposed Inhibitor of ERCC1/XPF for the Sensitization of Colorectal Cancer Cells to Platinum Chemotherapeutics. [PDF]

Mol Pharm
Mehinrad P, Abdelfattah A, Shafaati T, Emami J, Donnelly J, West FG, Weinfeld M, Lavasanifar A.   +7 more
europepmc   +1 more source

Crosstalk Between Intratumoral Microbes and Tumor Immunity: Implications for Tumor Therapy

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Emerging studies indicate that microbes are present in tumor cells and immune cells. Intratumoral microbiota (ITM) constitute an important component of the tumor immune microenvironment (TIME) and have an important impact on tumor progression and treatment. Objective Through the general elaboration of ITM represented by bacteria and
Fengxue Li, Lili Qiao, Xinquan Liang, Yingying Zhang, Ning Liang, Jian Xie, Guodong Deng, Yuying Hao, Pingping Hu, Xue Wu, Fangjie Ding, Can Feng, Yiming Mu, Jiandong Zhang   +13 more
wiley   +1 more source

Prospective assessment of serum neurofilament light chain in platinum-induced and taxane-induced peripheral neuropathy. [PDF]

BMJ Neurol Open
Smyth D, Keh RYS, Keddie S, Chou M, Hart M, Chapman M, Forster MD, Carr A, Lunn MP.   +8 more
europepmc   +1 more source

Comparative Effectiveness and Modality‐Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer

Cancer Medicine, Volume 15, Issue 2, February 2026.
ABSTRACT Background Neoadjuvant therapies, including chemotherapy (NACT), chemoradiotherapy (NACRT), and chemoimmunotherapy (NACIT), are standard for locally advanced gastric cancer (LAGC). Pathological response is a key surrogate for treatment effectiveness, but its correlation with long‐term outcomes across modalities remains unclear.
Yongfeng Zhu, Zhenchong Chen, Minju Jo, Shoucheng Feng, Yi Zeng, Xiaojiang Chen, Jianrong Guo, Chao Ding, Yukai Jin, Haibo Qiu   +9 more
wiley   +1 more source

Pressurized intraperitoneal aerosol chemotherapy enhances cisplatin efficacy in colorectal cancer organoids. [PDF]

Sci Rep
Kim SC, Lee SA, Kim MJ, Shin YK, Kim HS, Jeong SY, Ku JL, Park JW.   +7 more
europepmc   +1 more source

Minimal residual disease in solid tumors: Clinical applications and future directions

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Minimal residual disease (MRD) refers to the presence of residual cancer cells or tumor‐derived fragments that persist after treatment and remain undetectable by conventional imaging or protein‐based assays. Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker for MRD detection.
Theresa Abdo, Ahmad Alhalabi, Sacha Yaghi, Mohammad Aloran, You Li, María Herrán, Rami Tfayli, Thomas A. Samuel, Zeina Nahleh   +8 more
wiley   +1 more source

Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction. [PDF]

Ann Med
Li S, Liu J, Nie Z, Li H, Wang J.
europepmc   +1 more source